Zagazig Provincial Laboratory, Animal Health Research Institute, Zagazig, Egypt.
Department of Animal Medicine, Infectious Diseases, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt.
Open Vet J. 2024 Jan;14(1):19-24. doi: 10.5455/OVJ.2024.v14.i1.3. Epub 2024 Jan 31.
Brucellosis is a highly contagious zoonotic disease caused by an intracellular facultative microorganism termed spp. Control of brucellosis depends on test and slaughter policy as well as vaccination programs.
Estimation of the cell-mediated immunity (CMI) [total leukocytic count (TLC), phagocytic activity, phagocytic index, interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNF-α)] in camels after vaccination with RB51 using real-time polymerase chain reaction (PCR).
A total of eight camels were grouped into two groups as follows: group (A): vaccinated with RB51 vaccine [1 dose/2 ml S/C (3 × 10 CFU)] and group (B): control group. IL-6 and TNF-α were used for estimation of the CMI using real-time PCR on serum samples that were collected at 0, 7, 14, 21, 28, and 60 days after vaccination from each group. In addition, TLC, phagocytic activity, and phagocytic index were evaluated on heparinized blood samples at 0 and 60 days post-vaccination.
RB51 vaccine provides a protective immune response which progressively increases from the first week to 60 days after vaccination. Moreover, the levels of TNF-α and IL-6 differed between camels in the vaccinated group.
Vaccination of camels with RB51 vaccine (with dose 3 × 10 CFU) could induce good protective immune responses and this immunological response will be a good indication for a safe field vaccine that can be used for the control of camel brucellosis.
布氏杆菌病是一种由 spp 引起的高度传染性人畜共患病，是一种兼性胞内微生物。布氏杆菌病的控制依赖于检测和屠宰政策以及疫苗接种计划。
使用实时聚合酶链反应（PCR）估计 RB51 疫苗接种后骆驼的细胞介导免疫（CMI）[总白细胞计数（TLC）、吞噬活性、吞噬指数、白细胞介素 6（IL-6）和肿瘤坏死因子-α（TNF-α）]。
将 8 只骆驼分为两组：A 组（接种 RB51 疫苗[1 剂/2ml S/C（3×10 CFU）]）和 B 组（对照组）。使用实时 PCR 法，在接种后 0、7、14、21、28 和 60 天，从每组采集血清样本，测定血清中 IL-6 和 TNF-α，评估 CMI。此外，在接种后 0 和 60 天，用肝素化血液样本评估 TLC、吞噬活性和吞噬指数。
RB51 疫苗可提供保护免疫反应，从接种后第一周逐渐增加至 60 天。此外，接种组骆驼的 TNF-α 和 IL-6 水平不同。
用剂量为 3×10 CFU 的 RB51 疫苗接种骆驼可诱导良好的保护性免疫反应，这种免疫反应将是一种安全的现场疫苗的良好指标，可用于控制骆驼布氏杆菌病。
